Pfizer's post-COVID decline: how the COVID-vaccine boom that produced $100 billion in 2022 revenue collapsed to ~$60 billion by 2024 and triggered an oncology-bet strategy reset
Pfizer's 2022 revenue reached $100.3 billion — the highest annual revenue in pharma history, driven by COVID-19 vaccine Comirnaty and oral antiviral Paxlovid. By 2024, Pfizer's revenue had declined to approximately $60 billion as COVID demand normalized faster and more sharply than the company had projected. The decline produced strategic and financial pressure: layoffs of approximately 1,500 employees in 2024 plus prior workforce reductions; the $43 billion Seagen acquisition (closed December 2023) intended to rebuild oncology growth; the 2024 strategic shift toward $4 billion in annual cost savings by end of 2024; activist investor Starboard Value's October 2024 stake announcement and call for further changes; and stock decline from approximately $61 (December 2021) to under $25 (2024 trough). CEO Albert Bourla's tenure (since January 2019) is being increasingly questioned, with some investor calls for leadership change. The Pfizer 2022-2024 chapter is studied as a case in how pharma companies handle pandemic-era revenue surges and the inevitable normalization.
- Story: Pfizer's 2022 revenue reached $100.3B (highest in pharma history) driven by Comirnaty COVID vaccine and Paxlovid antiviral. By 2024 revenue collapsed to ~$60-64B as COVID demand normalized faster and sharper than projected. Strategic response: $43B Seagen acquisition (closed December 14, 2023) for oncology growth replacement; multiple smaller acquisitions 2022 (Biohaven, GBT, Arena); $3.5B cost-discipline program announced October 2023; ~1,500 layoffs in 2024. Activist Starboard Value took ~$1B stake October 2024 calling for changes. Stock fell from ~$61 (December 2021) to under $25 (2024 trough). CEO Albert Bourla continues; leadership question pressed by some investors.
- Why it matters: Pfizer 2022-2024 is the worked example of how companies handle pandemic-era revenue surges: surge revenue should fund strategic transitions, not sustained operating-expense expansion that assumes some portion of surge is permanent.
- Takeaway: One-time revenue surges should fund strategic optionality, not sustained operating-expense expansion.
- Takeaway: Acquisition timing matters: Pfizer's 2022-2023 acquisitions were funded by surge cash but priced based on surge-era valuations.
- Takeaway: Dividend commitments made during surge are difficult to walk back when revenue normalizes.
Pfizer post-COVID decline — the four-step story
Pfizer post-COVID decline at a glance
Quick facts
The 2020-2022 COVID-vaccine revenue surge
Pfizer's response to the COVID-19 pandemic produced one of the most dramatic pharma revenue stories in history. The Comirnaty vaccine (developed with BioNTech under accelerated FDA Emergency Use Authorization, EUA December 11, 2020) generated approximately $37 billion in 2021 revenue and approximately $37 billion in 2022. Paxlovid (Pfizer's oral COVID-19 antiviral, EUA December 22, 2021) generated approximately $19 billion in 2022 revenue.
Combined COVID-related revenue contributions:
- 2021 total revenue $81.3B: with COVID products contributing approximately $37B (45%+ of total).
- 2022 total revenue $100.3B: with COVID products contributing approximately $56B (55%+ of total).
- Operating income surge: Pfizer's 2022 operating income exceeded $35B, an enormous cash generation that gave the company unprecedented strategic flexibility.
- Stock peak: Pfizer stock reached approximately $61 in December 2021, reflecting both COVID-product performance and investor expectations of sustainable pandemic-era contribution.
- Strategic capital deployment: Pfizer pursued multiple acquisitions through 2022-2023 (Biohaven $11.6B 2022 for migraine, Global Blood Therapeutics $5.4B 2022 for sickle cell, Arena Pharmaceuticals $6.7B 2022, and others) plus the major Seagen acquisition announced March 2023.
- Pipeline investment: Pfizer raised R&D spending and announced ambitious post-COVID growth targets.
The post-pandemic normalization shock
Through 2023 and 2024, COVID-product revenue declined far faster than Pfizer had projected:
- 2023 Comirnaty revenue ~$11.2B: down 70% from 2022 peak as vaccination rates dropped.
- 2023 Paxlovid revenue ~$1.3B: down 93% from 2022 peak. Most countries (including US) transitioned from government purchasing to commercial market in 2023, dramatically reducing demand visibility.
- 2023 total revenue $58.5B: down 42% from $100.3B in 2022 — one of the largest year-over-year pharma revenue declines in modern history.
- 2024 COVID-product revenue guidance further reduced: continued Paxlovid weakness particularly visible, with Pfizer taking inventory writedowns and revenue revisions.
- Stock decline from $61 peak to under $25: ~60% decline reflecting both revenue collapse and questions about post-COVID strategic direction.
- Dividend pressure: Pfizer's substantial dividend ($1.68 annualized) became increasingly difficult to support given revenue and cash-flow trajectory.
The Seagen acquisition and the oncology pivot
On March 13, 2023, Pfizer announced it would acquire Seagen Inc. for $43 billion in cash (approximately $229 per Seagen share). The deal closed December 14, 2023. Strategic logic:
- Seagen's oncology portfolio: four FDA-approved cancer therapies (Adcetris, Padcev, Tukysa, Tivdak) plus a deep antibody-drug-conjugate (ADC) pipeline. Cumulative 2023 Seagen revenue was approximately $2.2B with strong growth.
- ADC platform: Seagen's ADC technology platform represented industry-leading capability in attaching cytotoxic agents to monoclonal antibodies. The platform produces drugs that target cancer cells specifically while sparing healthy cells.
- Replacement revenue thesis: Pfizer's argument was that Seagen oncology revenue would grow to $10B+ annually by 2030, replacing the declining COVID-era revenue with a more sustainable category.
- Antitrust review: FTC under Lina Khan reviewed extensively but ultimately allowed the deal to close.
- Acquisition financing: Pfizer funded with cash on hand plus $31B in new debt, substantially increasing leverage.
- Integration challenges: through 2024, integration produced typical large-pharma-acquisition friction (talent retention, R&D-pipeline rationalization, organizational integration). Seagen revenue contributed within Pfizer reporting at approximately $3.4B for 2024.
- Goodwill impairment risk: if Seagen's pipeline doesn't produce the projected revenue growth, Pfizer faces potential multi-billion-dollar writedowns over time.
The 2024 cost-discipline + activist pressure
Through 2024, Pfizer executed substantial cost-discipline initiatives:
- October 2023 cost-discipline announcement: $3.5B in cost savings targeted by end of 2024.
- Workforce reductions: approximately 1,500 layoffs announced 2024 plus prior reductions; cumulative pandemic-era hiring partially reversed.
- Manufacturing-capacity rationalization: some COVID-era manufacturing investment being repurposed or reduced.
- R&D pipeline rationalization: discontinuation of some pre-Seagen pipeline programs to focus resources.
- October 2024 Starboard Value stake announcement: activist investor Starboard Value (led by Jeff Smith) announced approximately $1B stake. Public letter cited concerns about Pfizer's strategic execution and called for board changes plus operational changes.
- Board response: Pfizer Chairman Albert Bourla publicly engaged with Starboard's concerns but defended the current strategic direction. Activist pressure continues into 2025.
- Albert Bourla leadership question: some investor and analyst voices have called for CEO change. Bourla has defended his tenure and the Seagen acquisition. Board has continued supporting Bourla; specific succession timing not publicly committed.
How RGM thinks about pandemic-era revenue surge management
Pfizer's 2022-2024 chapter is the worked example of how companies that experience extraordinary one-time revenue surges manage the inevitable normalization. The structural challenge: when revenue doubles due to pandemic-era demand, the temptation is to deploy the capital in ways that assume some portion of the surge is permanent. Pfizer's substantial acquisitions and operating-expense expansion in 2021-2023 were based on assumptions about post-COVID revenue persistence that proved too optimistic.
Our framework for clients in similar one-time-surge situations: the appropriate response is to treat the surge revenue as one-time cash that funds strategic transitions rather than as sustainable revenue that funds operating-expense expansion. Pfizer's Seagen acquisition (using surge cash for transformational M&A) was strategically defensible; the parallel operating-expense and headcount expansion (assuming COVID-era revenue would partially persist) was the questionable judgment. The 2024 cost-discipline is reversing the operating-expense expansion at substantial transition cost. We tell clients facing similar surge moments to be conservative about operating-expense expansion and to treat the cash as strategic optionality rather than sustainable revenue.
Frequently asked questions
Was Albert Bourla actually wrong about COVID revenue persistence?
In retrospect, yes about the magnitude of decline. Pfizer's 2023 guidance throughout 2022 had projected stronger 2023-2024 COVID revenue than actually materialized. The decline was both faster and sharper than industry consensus had projected. Whether the strategic decisions made under those assumptions (Seagen acquisition, operating expense expansion, dividend commitments) were genuinely wrong vs reasonable bets that didn't pay out is a separate question. Most analysts treat the strategic decisions as reasonable based on information available at the time but the operational discipline of execution has been criticized.
Is the Seagen acquisition working?
Early signs are mixed. Seagen oncology revenue is growing (to ~$3.4B 2024 within Pfizer reporting) but slower than the original $10B by 2030 trajectory would require. The ADC platform produces meaningful product opportunities but with typical multi-year drug-development timelines. Whether the $43B price will produce the projected returns will be clear by 2026-2028. Integration challenges have been typical for large pharma acquisitions.
What's Starboard Value pushing for?
Specifics not fully public. Reported priorities include: more aggressive cost discipline, potential strategic alternatives review for non-core businesses, board changes, possibly CEO change. Starboard's October 2024 letter was relatively soft compared to some activist letters; the engagement is ongoing. Whether Starboard escalates to proxy fight or settles for modest changes will likely be determined through 2025.
What about Pfizer's other major acquisitions?
Mixed. Biohaven ($11.6B 2022 for migraine; Nurtec ODT continues to grow). Global Blood Therapeutics ($5.4B 2022 for sickle cell; Oxbryta has produced revenue but FDA withdrawal in 2024 over safety concerns). Arena Pharmaceuticals ($6.7B 2022 for autoimmune; etrasimod approved as Velsipity 2023 but commercial uptake modest). The portfolio of recent acquisitions has been operationally challenging.
Will Pfizer cut the dividend?
Pfizer has publicly committed to maintaining the dividend but the math is increasingly tight. 2024 dividend payments are approximately $9B on free cash flow that has been compressed. If revenue declines further or Seagen integration costs exceed projections, dividend pressure could intensify. As of late 2024 the dividend remains intact but the situation requires monitoring.
Sources & references
- Pfizer 2023 annual report — Pfizer SEC filings and annual reports.
- Seagen acquisition close announcement — Pfizer December 14 2023 close announcement.
- Starboard Value stake coverage — WSJ October 2024 coverage of Starboard stake.
- COVID revenue decline coverage — Reuters coverage of 2024 guidance reductions.
- Albert Bourla strategic communications — Pfizer strategic communications.